Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome
NCT06285370Phase 4Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), Sézary syndrome (SS), sponsored by Kyowa Kirin. Started May 2023; status: completed.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT06285370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285370.